RESUMEN
PURPOSE: In the topical delivery of drugs to the lens, drug retention on the eye surface is considered to be important because increased retention on the ocular surface should lead to increased ocular absorption of a drug through the cornea into the aqueous humor and subsequently the lens. The aim of this study was to investigate whether increasing the viscosity of a topical aldose reductase inhibitor suspension increases the lenticular bioavailability of the inhibitor and whether such a formulation can arrest sugar cataract formation. METHODS: Five topical suspensions of 3% 2-methylsorbinil (2-MS) were prepared using (1) hydroxypropyl methylcellulose (HPMC, 0.5% w/v), (2) xanthan gum (0.5% w/v), (3) gellan gum (0.5% w/v), (4) carbopol (0.25% w/v), and (5) carbopol (0.25% w/v)--hydroxypropyl methylcellulose (HPMC) (0.25% w/v). Viscosity measurements were conducted with a viscometer. Lenticular levels of 2-MS were determined in the lenses from young Sprague Dawley rats receiving 1 drop of selected topical suspension twice-daily for 7 days. The efficacy of the suspensions to arrest sugar cataract formation was evaluated by administering the suspensions for 21 days to similar rats fed a diet containing 50% galactose. Lens changes were examined by portable slit lamp following mydriasis. RESULTS: Lenticular levels of 2-MS was highest in rats administered suspensions containing 0.25% carbopol + 0.25% HPMC as vehicles followed by 0.5% gellan gum, 0.5% HPMC, 0.25% carbopol, and 0.5% xanthan gum. All untreated rats fed a 50% galactose diet developed hypermature cataracts within 15 days; however, none of the topical treated rats demonstrated cortical vacuole formation after 21 days of galactose feeding. CONCLUSIONS: In the suspensions examined, no direct relationship between the lenticular drug levels of 2-MS and either viscosity or pH of the vehicles were observed. The observed arrest of sugar cataract formation indicated that therapeutically adequate lenticular levels of 2-MS were provided by all topical suspensions.
Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Catarata/tratamiento farmacológico , Inhibidores Enzimáticos/farmacología , Imidazolidinas/farmacología , Cristalino/efectos de los fármacos , Soluciones Oftálmicas/farmacología , Administración Tópica , Animales , Humor Acuoso , Disponibilidad Biológica , Transporte Biológico , Catarata/inducido químicamente , Córnea , Portadores de Fármacos , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacocinética , Galactosa , Concentración de Iones de Hidrógeno , Imidazolidinas/administración & dosificación , Imidazolidinas/farmacocinética , Cristalino/fisiopatología , Masculino , Midriasis , Soluciones Oftálmicas/administración & dosificación , Soluciones Oftálmicas/farmacocinética , Vehículos Farmacéuticos , Ratas , Ratas Sprague-Dawley , Vacuolas , ViscosidadRESUMEN
PURPOSE: To compare the systemic delivery of deslorelin following intratracheal administration of different deslorelin formulations. The formulations included dry powders of deslorelin, large-porous deslorelin-poly(lactide-co-glycolide) (PLGA) particles, and small conventional deslorelin-PLGA particles. Also, solution formulations of deslorelin and deslorelin-hydroxy-propyl-beta-cyclodextrin (HPbetaCD) complexes were tested. METHODS: Dry powders of deslorelin, large-porous (mean diameter, 13.8 microm; density, 0.082 g/cc), and small conventional (mean diameter, 2.2 microm; density, 0.7 g/cc) deslorelin-PLGA particles and solutions of deslorelin with or without HPbetaCD were administered intratracheally to Sprague-Dawley rats. Blood samples were collected at 3 h, 1, 3, and 7 days postdosing, and plasma deslorelin concentrations were determined using enzyme immunoassay. At the end of 7 days, lungs were isolated, and bronchoalveolar lavage fluid was collected and analyzed for deslorelin. RESULTS: At the end of 7 days, deslorelin plasma concentrations in the large-porous deslorelin-PLGA particle group were 120-fold and 2.5-fold higher compared to deslorelin powder and small conventional deslorelin-PLGA particles, respectively. Co-administration of HPbetaCD resulted in 2-, 3-, and 3-fold higher plasma deslorelin concentrations at 3 h, 1 and 3 days, respectively, compared to deslorelin solution. On day 7, deslorelin concentrations in bronchoalveolar lavage fluid as well as plasma were in the order: large porous particles > small conventional particles > deslorelin-HPbetaCD solution > deslorelin powder > deslorelin solution. CONCLUSIONS: Large-porous deslorelin PLGA particles can sustain deslorelin delivery via the deep lungs. Co-administration of HPbetaCD enhances the systemic delivery of deslorelin. The pulmonary route is useful as a noninvasive alternative for the systemic delivery of deslorelin.
Asunto(s)
Ácido Láctico/química , Pulmón/metabolismo , Ácido Poliglicólico/química , Polímeros/química , Pamoato de Triptorelina/análogos & derivados , Pamoato de Triptorelina/administración & dosificación , beta-Ciclodextrinas/química , 2-Hidroxipropil-beta-Ciclodextrina , Administración por Inhalación , Animales , Líquido del Lavado Bronquioalveolar/química , Portadores de Fármacos , Masculino , Tamaño de la Partícula , Soluciones Farmacéuticas , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Porosidad , Polvos , Ratas , Ratas Sprague-Dawley , Tráquea , Pamoato de Triptorelina/química , Pamoato de Triptorelina/farmacocinéticaRESUMEN
The nasal route is a non-invasive alternative route for the delivery of a number of macromolecules, including peptides, proteins and vaccines. The purpose of this study was to determine the regional variation in excised bovine nasal tissue permeability to deslorelin, a nonapeptide luteinizing hormone releasing hormone (LHRH) agonist, and to further elucidate its mechanisms of transport. To this end, this study determined the permeability of deslorelin across different regions of freshly excised bovine nasal mucosa, including the medium turbinate anterior (MTA), medium turbinate posterior (MTP) and the inferior turbinate posterior (ITP) regions. At 37 degrees C, mucoal-to-serosal (m-s) transport of deslorelin across excised bovine nasal mucosa exhibited regional variation, with the % cumulative transport in 6 h being in the order: MTA (0.2 +/- 0.06%) < MTP (1.6 +/- 0.1%) < ITP (2.85 +/- 0.3%). In addition, at 37 degrees C, deslorelin transport across all these nasal regions was vectorial and the mucosal-to-serosal:serosal-to-mucosal (m-s:s-m) transport ratios across MTA, MTP and ITP regions were 1.5, 5.4 and 3.7, respectively. At low temperature (4 degrees C) and at 37 degrees C in the presence of 2,4-dinitrophenol, an energy depletor, the m-s deslorelin transport across the MTP region decreased to 0.32 +/- 0.12 and 0.13 +/- 0.05%, respectively, and the directionality was abolished. Sodium fluorescein transport also exhibited regional variation but no directionality. Histology and scanning electron microscopy studies indicated non-ciliated columnar epithelium in the MTA region and ciliated respiratory epithelium in the MTP and ITP regions. The thickness of the various regions, as visualized using histology, was in the order: MTA > MTP > ITP. Thus, deslorelin transport across excised bovine nasal mucosa is vectorial, temperature- and energy-dependent and exhibits regional variation. The regional differences in s-m transport are likely due to differences in the passive transport. Differences in m-s:s-m flux ratios may be due to differential expression of carriers.
Asunto(s)
Inhibidores Enzimáticos/farmacocinética , Mucosa Nasal/metabolismo , Pamoato de Triptorelina/análogos & derivados , Pamoato de Triptorelina/farmacocinética , Animales , Transporte Biológico , Bovinos , Permeabilidad de la Membrana Celular , Técnicas In Vitro , Microscopía Electrónica de Rastreo , Mucosa Nasal/anatomía & histología , Temperatura , Cornetes Nasales/anatomía & histologíaRESUMEN
PURPOSE: To determine whether LHRH-receptor is expressed in Calu-3, a human bronchial epithelial cell line, and to further determine whether this receptor plays a role in the transport of deslorelin, an LHRH agonist. METHODS: Using cultured monolayers of Calu-3 grown at air-interface, the presence and localization of LHRH-receptors in Calu-3 cells was determined using immunochemical methods. To determine the mechanisms of deslorelin transport, the directionality [apical-basolateral (A-B) and basolateral-apical (B-A)] of deslorelin transport across Calu-3 monolayers and the effects of temperature (37 degrees C and 4 degrees C) and an energy depletor (2,4-dinitrophenol) were investigated. To determine the role of LHRH-receptor in deslorelin transport across Calu-3 monolayers, the influence of an LHRH-receptor antisense oligonucleotide on the LHRH-receptor expression and deslorelin transport was studied. Also, the effect of a competing LHRH agonist, buserelin, on deslorelin transport was determined. RESULTS: Immunofluorescence studies indicated the predominance of LHRH-receptor in Calu-3 cells at the apical and lateral surfaces. Western blot and RT-PCR studies further confirmed the expression of LHRH-receptor in Calu-3 cells. Deslorelin transport across Calu-3 monolayers was vectorial, with the cumulative A-B transport (1.79 +/- 0.29%) at the end of 240 min being higher than the B-A transport (0.34 +/- 0.11%). Low temperature as well as 2,4-dinitrophenol abolished this directionality. LHRH-receptor antisense oligonucleotide decreased the receptor expression at the mRNA and protein level and reduced the A-B deslorelin transport by 55 +/- 4%, without affecting the B-A transport, suggesting a role for LHRH-receptor in the vectorial transport of deslorelin. In addition, buserelin reduced the A-B deslorelin transport by 56 +/- 5% without affecting the B-A transport. CONCLUSIONS: Taken together, our results provide evidence that deslorelin is transported across the respiratory epithelium via the LHRH-receptor.
Asunto(s)
Buserelina/farmacocinética , Células Epiteliales/citología , Expresión Génica/genética , Receptores LHRH/genética , Sistema Respiratorio/citología , Pamoato de Triptorelina/análogos & derivados , Pamoato de Triptorelina/farmacocinética , 2,4-Dinitrofenol/farmacología , Animales , Transporte Biológico , Western Blotting/métodos , Buserelina/farmacología , Bovinos , Línea Celular , Impedancia Eléctrica , Células Epiteliales/fisiología , Técnica del Anticuerpo Fluorescente/métodos , Humanos , Oligorribonucleótidos Antisentido/farmacología , ARN Mensajero , Ratas , Receptores LHRH/antagonistas & inhibidores , Receptores LHRH/inmunología , Sistema Respiratorio/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Temperatura , Factores de Tiempo , Pamoato de Triptorelina/farmacologíaRESUMEN
PURPOSE: The purpose of this study was to prepare large-porous peptide-encapsulating polymeric particles with low residual solvent that retain deslorelin integrity, sustain drug release, and exhibit reduced epithelial and macrophage uptake. We hypothesized that supercritical carbon dioxide (SC CO2) pressure-quench treatment of microparticles prepared using conventional approach expands these particles and extracts the residual organic solvent. METHODS: Initial studies with crystalline L-lactide (L-PLA) and amorphous copolymers of lactide-co-glycolide (PLGA) 50:50, 65:35, and 75:25 indicated that PLGA 50:50 was the most amenable to morphological changes upon SC CO2 treatment. Therefore, we prepared deslorelin-PLGA (50:50) microparticles using the conventional emulsion-solvent evaporation method, and in a second step equilibrated with SC CO2 at various temperatures (33-37 degrees C) and pressures (1200-2000 psi) for discrete intervals followed by rapid isothermal depressurization. The particles were then characterized for morphology, polymer thermal properties, particle size, porosity, bulk density, and residual solvent content. Also, deslorelin integrity, conformation, release, and cellular uptake before and after SC CO2 treatment was determined. RESULTS: Upon SC CO2 treatment (1200 psi, 33 degrees C for 30 min), the mean particle size of the deslorelin PLGA microparticles increased from 2.2 to 13.8 microm, the mean porosity increased from 39 to 92.38% the mean pore diameter increased from 90 to 190 nm, the mean bulk density reduced from 0.7 to 0.082 g/cc, mass spectrometry indicated structural integrity of released deslorelin, the circular dichroism spectrum indicated stabilization of beta-turn conformation, and the scanning electron microscopy confirmed increased particle size and pore formation. The deslorelin release was sustained during the 7-day study period. Also, the peak Tg of PLGA decreased from 51 to 45 degrees C, and the residual solvent content was reduced from 4500 ppm to below detection limit (< 25 ppm). The accumulation of drug from SC CO2 treated particles in cell layers of Calu-3, A549, and rat alveolar macrophages was reduced by 87, 91 and 50%, respectively, compared to untreated particles. CONCLUSION: An SCF-derived process could be successfully applied to prepare large porous deslorelin-PLGA particles with reduced residual solvent content, which retained deslorelin integrity, sustained deslorelin release, and reduced cellular uptake.
Asunto(s)
Dióxido de Carbono , Polímeros , Animales , Dióxido de Carbono/química , Microscopía Electrónica de Rastreo , Tamaño de la Partícula , Polímeros/química , Porosidad , Solventes/químicaRESUMEN
PURPOSE: The objective of this study is to investigate the pathways and kinetics of degradation of deslorelin, pGlu1-His2-Trp3-Ser4-Tyr5-D-Trp6-Leu7-Arg8-ProNHEt9 (Des1-9), in a human airway epithelial cell line (Calu-1). METHODS: The degradation of deslorelin in membrane and cytosolic fractions of Calu-1 cells was studied at 37 degrees C up to 24 h. The degradation products were separated using HPLC and identified by amino acid analysis, sequencing, and mass spectrometry. The rate constants for deslorelin degradation and the formation of degradation products were determined by fitting the concentration vs. time data to pharmacokinetic models using WinNonlin. The effect of enzyme inhibitors, captopril, phosphoramidon, and disodium EDTA on deslorelin degradation was also assessed. RESULTS: Des1-3, Des4-9, and Des5-9 were the deslorelin fragments detected in the membrane fraction. Apart from these degradation products. Des5-7 was also detected in the cytosolic fraction. The deslorelin degradation was 8.5 times faster in the cytosolic fraction compared to the membrane fraction. The disappearance of deslorelin and the kinetics of degradation products could be explained by simple 2 compartment iv bolus model and 1 compartment absorption model, respectively. EDTA and captopril decreased deslorelin degradation in the membrane and cytosolic fractions. CONCLUSIONS: Deslorelin is initially cleaved at the 3-4 bond in the membrane and cytosolic fractions, possibly by a metalloendopeptidase and/or angiotensin converting enzyme, with the degradation being more rapid in the cytosol.
Asunto(s)
Mucosa Respiratoria/metabolismo , Transducción de Señal/fisiología , Pamoato de Triptorelina/análogos & derivados , Pamoato de Triptorelina/farmacocinética , Línea Celular Tumoral/efectos de los fármacos , Línea Celular Tumoral/metabolismo , Citosol/metabolismo , Inhibidores Enzimáticos/farmacología , Humanos , Mucosa Respiratoria/citología , Transducción de Señal/efectos de los fármacos , Pamoato de Triptorelina/análisisRESUMEN
The objective of this study was to compare the effectiveness of intramuscular sustained release Pluronic F127 (PF127) gel formulations of deslorelin, a potent GnRH agonist, and GnRH to their solution formulations in inducing the release of luteinizing hormone and formation of luteal tissue in cattle. Injectable gel formulations of deslorelin and GnRH were prepared using Pluronic F127 (25%, w/w), a block copolymer. PF127 gels sustained the in vitro release of deslorelin as well as GnRH at similar rates and reduced drug degradation in muscle tissue when compared to the solution formulations. Deslorelin, as well as GnRH, elicited desirable elevations in plasma LH and progesterone concentrations in vivo. When compared to the solution formulations, the gel formulations of both drugs induced a broader peak of LH. Also, the peak LH levels were lower and the peak times were delayed with the gel formulations compared to the solution formulations. While the solution dosage form of deslorelin and GnRH elicited similar responses, the PF127 gel formulation of deslorelin induced peak LH levels at an earlier time (3 h for deslorelin versus 5.25 h for GnRH). The results indicate that, deslorelin exerts a pharmacological effect in cattle. The LH response to deslorelin as well as GnRH can be altered by controlling the input or the release rate of the drug. PF127 gel formulations can sustain peptide release and reduce peptide degradation.